Merck Announced Results From Stride-8 Phase Trial Of Capvaxive Compared To PCV15 In Combination With PPSV23 In Vaccine-naïve Adults 18-64 Years, With Certain Chronic Conditions, Demonstrates Immune Responses In Adults With Increased Risk For Pneumococcal Disease
Portfolio Pulse from Benzinga Newsdesk
Merck announced results from the Stride-8 Phase trial of Capvaxive, showing immune responses in adults with increased risk for pneumococcal disease. The trial compared Capvaxive to PCV15 in combination with PPSV23 in vaccine-naïve adults aged 18-64 with certain chronic conditions.
October 16, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Stride-8 Phase trial results for Capvaxive indicate positive immune responses in at-risk adults, potentially boosting investor confidence in Merck's vaccine portfolio.
The positive results from the Stride-8 Phase trial of Capvaxive suggest that Merck's vaccine could be effective for adults at increased risk for pneumococcal disease. This could enhance Merck's vaccine portfolio and lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90